Nasal Oxcytocin During IUI

• Status: Completed
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Placebo-controlled study. Application of nasal oxytocin (8 IU) during intrauterine insemination in 86 patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ludwig-Maximilians - University of Munich
• Collaborators: Essex Pharma GmbH; Organon GmbH (former name)
• Treatments: Oxytocin

Criteria

Inclusion Criteria:

• Inclusion criteria for couples were idiopathic infertility, polycystic ovary syndrome (PCOS) and / or male subfertility.

• Age 18-42

• In all patients fallopian tubes were documented to be patent by sonographic contrast hysterosalpingography (Echovist® 200, Bayer Vital GmbH, Leverkusen, Germany) or by chromo-laparoscopy.

• Infections with Hepatitis B and C and HIV were excluded in all couples by negative serological tests.

• In all patients protective titers against rubella virus were confirmed.

Exclusion Criteria:

• Patients displaying signs or symptoms of anomalies such as uterine fusion defects, submucosal fibroids, active endometriosis or acute inflammation were excluded from the study.

• Further prerequisites were endocrine serum parameters (FSH, LH, estradiol, testosterone, SHBG, DHEA-S, Prolaktin, TSH) from cycle day 2-5 within the normogonadotropic range with no evidence of hyperandrogenemia, thyroid dysfunction or hyperprolactinemia. 1